Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07509034) titled 'Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease' on April 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Extensive-Stage Small Cell Lung Cancer
Extrapulmonary Neuroendocrine Carcinoma
Recurrent or Refractory
Solid Tumors
Intervention:
Drug: Autologous B7-H3 CAR T
Drug: Cyclophosphamide
Recruitment Status: Not recruiting
Phase: ...